HCC - HEPATOCELLULAR CARCINOMA
Clinical trials for HCC - HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HCC - HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for HCC - HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Triple therapy shows promise for tough liver cancer cases
Disease control CompletedThis study tested whether adding a liver-directed chemotherapy infusion (HAIC) to the usual combination of lenvatinib and a PD-1 inhibitor improves outcomes for people with advanced liver cancer that has spread into the portal vein. 244 patients with high tumor burden were includ…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated May 26, 2026 12:04 UTC
-
Triple drug cocktail shows promise against tough liver cancer
Disease control CompletedThis study tested whether adding a third drug, ipilimumab, to a two-drug combination (atezolizumab and bevacizumab) helps people with advanced liver cancer live longer. 229 patients received either the two-drug or three-drug regimen. The goal was to see if the triple therapy impr…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Disease control
Last updated May 26, 2026 12:04 UTC
-
Liver cancer patients get a second chance with combo drug add-on
Disease control CompletedThis study tested whether adding lenalidomide could help people with advanced liver cancer whose tumors kept growing despite standard treatment with lenvatinib and immunotherapy. Researchers tracked 24 patients to see how long they lived without the cancer getting worse. The goal…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: NA • Sponsor: Beijing Tsinghua Chang Gung Hospital • Aim: Disease control
Last updated May 22, 2026 14:05 UTC